Biotherapeutics University College Dublin

Overview

The M.Sc. in Biotherapeutics at University College Dublin provides students with a comprehensive education in the discovery and development of protein-based drug candidates. This advanced curriculum bridges the gap between pre-clinical modelling and the industrial bioprocessing required for modern medicine. Participants explore the entire pipeline, from initial target identification to the final characterisation of antibodies.

The programme integrates systems biology and proteomics-based discovery with mathematical modelling and bioinformatics. Students also examine the regulatory frameworks and commercialisation strategies essential for bringing new biotherapeutics to market. A significant portion of the degree is dedicated to a six-month laboratory project, offering immersive experience in a professional research setting.

Why Biotherapeutics at University College Dublin?

Students benefit from expert faculty and senior industry practitioners who are leaders in the biopharmaceutical sector. The university provides hands-on experience in bioprocessing and access to the National Institute for Bioprocessing Research and Training (NIBRT) located on campus. This unique partnership ensures that learners use state-of-the-art facilities and engage with high-tech research laboratories throughout their studies.

Tuition Fee Breakdown

• International fee: EUR 29100 per year
• European fee: EUR 12810 per year

Visit the Fees and Funding section for a breakdown in your local currency.

Syllabus

The curriculum is designed to cover the full spectrum of drug development and biotechnological processes. Modules may include:

• Project in Biotherapeutics Dev
• Professional Career Development
• Biotherapeutic Pipeline
• Systems Biology in Drug Dev
• Biomedical Diagnostics
• Business of Biotechnology and Science
• Recombinant DNA Technology
• Microbial and Animal Cell Products
• Bioprocessing

Careers with Biotherapeutics

This degree was developed in close consultation with the biopharmaceutical industry to ensure graduates meet current employer demands. The significant drug discovery project is reviewed by industry partners, helping students build professional networks early in their careers. Graduates are well-prepared for roles in global organisations involved in medicine manufacturing and research.

Prospective employers for graduates of this programme include major international firms such as Novartis, GSK, Eli Lilly and Co., and Pfizer. Other potential destinations include Janssen Biologics, AstraZeneca, MSD, Bristol Myers Squibb, Abbott, and Sanofi. The focus on both technical skills and regulatory affairs makes alumni highly competitive in the global life sciences job market.